Literature DB >> 10959903

Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease.

C Hoppe1, E Vichinsky, K Quirolo, J van Warmerdam, K Allen, L Styles.   

Abstract

The efficacy and side effects of hydroxyurea in young children with sickle cell disease are unknown. The authors followed-up eight young children (mean age 3.7 years) during therapy with hydroxyurea for an average of 137 weeks. Total and fetal hemoglobin levels rose with hydroxyurea therapy. Hospital admission rates and total hospital days decreased during hydroxyurea therapy. No unexpected toxicity occurred, and growth and development were unaffected. This pilot study suggests that hydroxyurea is safe and effective in young children with sickle cell disease.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10959903     DOI： 10.1097/00043426-200007000-00009

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN： 1077-4114            Impact factor:   1.289


  10 in total

1.  Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study.

Authors:  Jane S Hankins; Russell E Ware; Zora R Rogers; Lynn W Wynn; Peter A Lane; J Paul Scott; Winfred C Wang
Journal:  Blood       Date:  2005-10-01       Impact factor: 22.113

2.  Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial.

Authors:  M Beth McCarville; Zhaoyu Luo; Xiangke Huang; Renee C Rees; Zora R Rogers; Scott T Miller; Bruce Thompson; Ram Kalpatthi; Winfred C Wang
Journal:  AJR Am J Roentgenol       Date:  2011-06       Impact factor: 3.959

Review 3.  How I use hydroxyurea to treat young patients with sickle cell anemia.

Authors:  Russell E Ware
Journal:  Blood       Date:  2010-03-11       Impact factor: 22.113

Review 4.  State of the Art Management of Acute Vaso-occlusive Pain in Sickle Cell Disease.

Authors:  Latika Puri; Kerri A Nottage; Jane S Hankins; Doralina L Anghelescu
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

Review 5.  Sickle cell anaemia: epidemiology and cost of illness.

Authors:  Paul J Nietert; Marc D Silverstein; Miguel R Abboud
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

6.  The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design.

Authors:  Bruce W Thompson; Scott T Miller; Zora R Rogers; Renee C Rees; Russell E Ware; Myron A Waclawiw; Rathi V Iyer; James F Casella; Lori Luchtman-Jones; Sohail Rana; Courtney D Thornburg; Ram V Kalpatthi; Julio C Barredo; R Clark Brown; Sharada Sarnaik; Thomas H Howard; Lori Luck; Winfred C Wang
Journal:  Pediatr Blood Cancer       Date:  2010-02       Impact factor: 3.167

7.  Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease.

Authors:  Suzette O Oyeku; M Catherine Driscoll; Hillel W Cohen; Rebecca Trachtman; Farzana Pashankar; Craig Mullen; Patricia J Giardina; Nerissa Velazco; Andrew D Racine; Nancy S Green
Journal:  Pediatr Blood Cancer       Date:  2012-11-05       Impact factor: 3.167

8.  Hydroxyurea therapy mobilises arachidonic Acid from inner cell membrane aminophospholipids in patients with homozygous sickle cell disease.

Authors:  A A Daak; K Ghebremeskel; M I Elbashir; A Bakhita; Z Hassan; M A Crawford
Journal:  J Lipids       Date:  2011-09-15

9.  Side effects of hydroxyurea in patients with Thalassemia major and thalassemia intermedia and sickle cell anemia.

Authors:  A Ghasemi; B Keikhaei; R Ghodsi
Journal:  Iran J Ped Hematol Oncol       Date:  2014-07-20

10.  Patients with sickle cell disease taking hydroxyurea in the Hemocentro Regional de Montes Claros.

Authors:  Fernanda Kelle de Souza Santos; Caroline Nogueira Maia
Journal:  Rev Bras Hematol Hemoter       Date:  2011
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.